A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

BACKGROUND: RET rearrangements are found in 1–2% of non-small cell lung cancers. Cabozantinib is a multikinase RET inhibitor that produced a 10% response rate in unselected patients with lung cancers. To evaluate the activity of cabozantinib in patients with RET-rearranged lung cancers, we conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Rekhtman, Natasha, Arcila, Maria, Wang, Lu, Ni, Andy, Albano, Melanie, Van Voorthuysen, Martine, Somwar, Romel, Smith, Roger S., Montecalvo, Joseph, Plodkowski, Andrew, Ginsberg, Michelle S., Riely, Gregory J., Rudin, Charles M., Ladanyi, Marc, Kris, Mark G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143197/
https://www.ncbi.nlm.nih.gov/pubmed/27825636
http://dx.doi.org/10.1016/S1470-2045(16)30562-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143197/
https://www.ncbi.nlm.nih.gov/pubmed/27825636
http://dx.doi.org/10.1016/S1470-2045(16)30562-9

Ejemplares similares